chrisvoncsefalvay/vaers-outcomes huggingface dataset:
A friend of mine got her first dose today and seems to have an allergic reaction; rash; swelling; tingling in her neck and face; This spontaneous case was reported by a consumer and describes the occurrence of ALLERGY TO VACCINE (A friend of mine got her first dose today and seems to have an allergic reaction), RASH (rash), SWELLING (swelling) and PARAESTHESIA (tingling in her neck and face) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ALLERGY TO VACCINE (A friend of mine got her first dose today and seems to have an allergic reaction), RASH (rash), SWELLING (swelling) and PARAESTHESIA (tingling in her neck and face). At the time of the report, ALLERGY TO VACCINE (A friend of mine got her first dose today and seems to have an allergic reaction), RASH (rash), SWELLING (swelling) and PARAESTHESIA (tingling in her neck and face) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.   No treatment information was provided.
Tested positive for covid-19 after first dose of the vaccine; This spontaneous case was reported by an other health care professional and describes the occurrence of SARS-COV-2 TEST POSITIVE (Tested positive for covid-19 after first dose of the vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SARS-COV-2 TEST POSITIVE (Tested positive for covid-19 after first dose of the vaccine). At the time of the report, SARS-COV-2 TEST POSITIVE (Tested positive for covid-19 after first dose of the vaccine) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   No concomitant medication reported. No treatment information was provided   Reporter did not allow further contact
Pt received second Moderna vaccine on 8/3 and on 8/4 developed redness and pain at the injection site. She presented to our ER on 8/8 c/o arm being red, swollen and painful. She was given 1gm ancef IM and d/c with tylenol #3 and bactrim rx. She returned to the ER on 8/9/21 with increased swelling, pain and redness concerning for cellulitis. She was given fluids, zosyn and admitted to med surg for observation with diagnosis of cellulitis in the left upper arm.
A physician reported that a child received a dose of Prevnar and subsequently, experienced flu-like symptoms. The reporter indicated that several children experienced this event following receipt of Prevnar; however, they are not presently identifiable. Additional reports will be generated when identifying information is provided.
First noted petechaie on the morning of the 5th, it got worse the next day.  Diagnosed with ITP, platelets of 11.  Now diagnosed with aquired aHUS 6/28/14.
pt given 2nd Moderna booster this morning (08/02/22 @ 9:15)...vial had been opened on 08/01/22 @ 9:30
40mm x 30mm area of redness on lt arm;c/o h/a & arm pain;mom stated pt felt hot last noc & gave APAP;
I had the vaccine on Wednesday and Friday morning i woke up with a headache; feeling hot and clamy; feeling hot and clamy; nausios; i could not breathe; It was like a really bad asthma attack; This is a spontaneous report received from a contactable consumer (patient).   A 54-year-old female patient received the 1st dose of bnt162b2 (BNT162B2, Lot # EN6208), via an unspecified route of administration i as single dose in arm left on 10Mar2021 for COVID-19 immunisation.  Medical history included known allergy to penicillin. The patient's concomitant medications were not reported. The patient has not received other vaccines within 4 weeks prior to the COVID vaccine. On 12Mar2021 04:30 morning the patient experienced woke up with a headache, feeling hot and clamy, nausios. She took Iboprofin and was fine. On 12Mar2021 night she went to bed about 10 pm and woke up from a sound sleep about 12:30 am she could not breathe. It was like a really bad asthma attack which she have never had like that. It took a while to try to breath thru her nose but finally she was able to and took a nebulizer treatment with Abutero. She was very scary. She was wondering if she should take the 2nd dose. The events were considered life threatening. Therapeutic measures were taken as a result of events. Covid was not tested post vaccination. The outcome of events was not recovered.
4 CM x 4 CM SWOLLEN SPOT ON RIGHT ARM, NOT RED, NOT WARM, MIDLY TENDER
I administered 1 ml.  the correct dose is 0.5 ml.   Patient has no adverse event.
About 30 minutes after the injection I noticed a slight tingling /numbness on the left side of my body to my midline. I noticed it in my lips, in my arm, and in my left foot. On day two, the numbness/tingling was worse in my left arm and especially in my fingers and my left hip joint aches and I feel tingling/ache down my leg.
Initial misuse report received from a healthcare professional on 09 July 2013. A patient (in an adult age group, no information was provided regarding the patient), had received DAPTACEL vaccine instead of ADACEL vaccine. Thus the vaccine was administered at an inappropriate age. No adverse event was reported. Documents held by sender: None
Patient received vaccination yesterday. today she presented to the pharmacy with a red and indurated rash across the top and upper portion of her left arm around injection site. The patient described it was "warm to touch" and "uncomfortable".
Adverse Event: Swelling of right upper arm from injection site down to elbow (19 cm lateral arm) with redness. Treatment: Benadryl every 6 hours as needed. Outcome: To be determined.
ACUTE DVT, UNSPECIFIED VEIN ACUTE HYPOXEMIC RESPIRATORY FAILURE ACUTE PULMONARY EMBOLISM CHRONIC HYPOXEMIC RESPIRATORY FAILURE RESPIRATORY FAILURE, UNSPECIFIED ACUITY
At injection site, 4 days after the 2nd injection, had a large hive.  Red, itchy, lasted a few days.
Closed fracture of left hip. ED visit, surgery and hospital admission. This visit was within 6 weeks of receiving the COVID vaccine.
Fever for 2 days / As high as 103.3 / Every 6 hours for 36 hours; Headache; Muscle and joint pain; Muscle and joint pain; Pain at injection; The patient received a third/booster dose; The patient received a third/booster dose; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 30130BA) via an unspecified route of administration in the left arm on 01Oct2021 at 12:30 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration on 01Mar2021 (at the age of 60-years-old) and also previously received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration on 31Mar2021 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. On 02Oct2021, the patient experienced fever for two days, as high as 103.3, every 6 hours for 36 hours, headache, muscle and joint pain and pain at injection. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the event fever which included fever reducing medication. On 02Oct2021, the patient underwent body temperature test and the result was 103.3 (unspecified units). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event fever as high as 103.3, every 6 hours for 36 hours was resolved with sequalae on 04Oct2021 while headache, muscle and joint pain and pain at injection was resolved with sequelae on an unknown date in Oct2021 at the time of this report.
Pt presents to clinic for ER F/U. Pt per mother had a seizure last night after receiving 4th pneumococcal vaccine yesterday in clinic. Pt was having fevers relived within Motrin. Mom states that pt lost consciousness and she had to perform CPR. Pt was taken to med ctr and evaluated and released. Only abdominal lab was CBC. Pt feeling well this AM. No other problems.
Soreness in left arm; Headache; Nausea; Fever of 100.5 degrees; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Soreness in left arm), HEADACHE (Headache), NAUSEA (Nausea) and PYREXIA (Fever of 100.5 degrees) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 31-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Feb-2021, the patient experienced PAIN (Soreness in left arm), HEADACHE (Headache), NAUSEA (Nausea) and PYREXIA (Fever of 100.5 degrees). At the time of the report, PAIN (Soreness in left arm), HEADACHE (Headache), NAUSEA (Nausea) and PYREXIA (Fever of 100.5 degrees) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 01-Feb-2021, Body temperature: 100.5 (High) 100.5 degree.         No relevant concomitant medications were reported. No treatment information was provided.
Breakthrough case admission after 2 vaccines MOderna 2/8/21 Lot# 007M20A;  Moderna 3/8/21 NO LOT NUMBER  THIS INFORMATION IS NOT IN THE STATE OF DATABASE
Half dose Administered; needle of syringe was defective and broken; This spontaneous case was reported by a pharmacist and describes the occurrence of UNDERDOSE (Half dose Administered) and NEEDLE ISSUE (needle of syringe was defective and broken) in a 34-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Apr-2021, the patient experienced UNDERDOSE (Half dose Administered) and NEEDLE ISSUE (needle of syringe was defective and broken). On 22-Apr-2021, UNDERDOSE (Half dose Administered) and NEEDLE ISSUE (needle of syringe was defective and broken) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered UNDERDOSE (Half dose Administered) and NEEDLE ISSUE (needle of syringe was defective and broken) to be not applicable.    Concomitant and treatment information not provided.
Tested positive before 2nd dose; Tested positive before 2nd dose; This is a spontaneous report from a Pfizer-sponsored program. A contactable consumer reported a female patient of unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route on an unspecified date as a single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. On an unknown date, the patient tested positive for COVID-19 before the second dose of BNT162B2. The outcome of tested positive before 2nd dose was unknown.  The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow-up.
After Pt received 1st Dose of Pfizer she felt Nauseated and lightheaded.  Crackers and water was given to Pt and symptoms resolved.
Nystagmus morning after vaccine. Resolved in 1/2 hour. Patient went to PCP and opthamalogist on 11/6. Had a scan on eye.
Pain at the injection site-mild; Mild fever; chills; body ache; generalized exhaustion; This is a spontaneous report from a contactable Physician. This 47-year old male Physician(patient) reported.  A 47-years-old male patient received bnt162b2 (BNT162B2, Batch/Lot number was unknown) (Misplaced/discarded) via intramuscular route of administration, administered in Arm Left on 21Jan2021 14:00 as dose 2, single for covid-19 immunisation (age at the vaccination 47 years old). The historical drug bnt162b2 (BNT162B2, Batch/Lot number was unknown) via intramuscular route of administration, administered in Arm Left on 31Dec2020, 09:00 as dose 1, single for covid-19 immunisation. The medical history was no known allergies. and concomitant medication was not reported. The patient experienced pain at the injection site-mild Mild fever, chills, body ache and generalized exhaustion on 22Jan2021 02:00. The patient received the acetaminophen 1 gm oral tablet 24 hours after the vaccination as a treatment. The patient was not covid prior vaccination: and not covid tested post vaccination. Lab data included mild fever on 22Jan2021. The outcome of the events was recovered on an unspecified date in 2021.   Follow-up (11May2021): Follow-up attempts completed. No further information expected.
Patient (I) woke up the day after second dose of covid-19 vaccine with seven (7) painful cystic pimples, the size of a pea or smaller, along the very edge of jawline (placement was exactly on top of lower jawbone) stretching from in front of one ear to just underneath the other ear. These were different than swollen lymph nodes. (Patient has a history of cystic acne, but has not experienced it for several years.) Four of the cysts went away on their own in about 4-5 days. Two more lasted about 8 days. The seventh cyst persists without the presence of pain as of today, 18 days after injection.  Zero other adverse effects were experienced after this vaccine; not even a sore injection site. (Patient experienced swollen lymph nodes in left underarm after first dose of covid-19 vaccine, but not after second dose.)
Site: Bruising at Injection Site-Medium, Site: Itching at Injection Site-Medium, Site: Redness at Injection Site-Medium, Additional Details:  stated she had been scratching the injection site. That may have led to the stated reactions
Nearly three week after getting the first vaccine from Pfizer, I started to experience numbness in my face.   On Saturday night (May 8th) I expressed to me wife that I noticed that I couldn't close my mouth all the way, and my face was really numb.   When I woke up Sunday morning the entire right side of my face was paralyzed. I was unable to close my right eye, flare my right nostril, open the right side of my mouth.  We went directly to the hospital thinking I was having a stroke, and it was there that I was diagnosed with Bells Palsy.
This spontaneous report was received from a physician concerning an unknown number of patients (demographics unknown). On unknown dates the patients were vaccinated with improperly stored doses of ROTATEQ (dose, route, lot # not provided). No adverse symptoms were reported. This is one of several reports received from the same source. Additional information has been requested.
On Saturday developed big round spot on arm, hot to touch. Other symptoms-Nausea, dizzy, no energy, slept all day, vomited, no appetite. On Monday developed blisters in mouth. Site where injection was given still hot to touch and purple in color.
redness and warmth 10 days post injection distal to the injection site. PCP recommended cold compresses and 7 days of antibiotics. Warmth is decreasing, redness remains
per mother, pt splayed out chair and body was shaking, which lasted a few seconds. Pt reports, that it felt like he was dreaming. Mother informed me immediately. Pt was oriented by the time I came. EMT was called and they took vitals. Pt was bradycardic and hypotensive. He also reported neck pain. He was then taken to the hospital.
This spontaneous report was received from a nurse and refers to a 2-year-old patient of unknown gender. The patient's pertinent medical history, concomitant medications and drug reactions or allergies were not reported. On 10-NOV-2016, the patient received simultaneously a dose of PROQUAD (recombinant human albumin, rHA) (lot # M022402 with expiration date at 01-NOV-2017; dose and route of administration were not reported) and a dose of VARIVAX (lot # M025864 with expiration date at 24-MAY-2018; dose and route of administration were not reported). There were no adverse events reported. No product quality complaint (PQC) was involved. Additional information has been requested.
Vaccine status completed +booster Patient is a 78-year-old patient with history of stage I lung cancer.  The patient says she has experienced worsening shortness of breath, fatigue, dry cough and night sweats over the past 3 weeks.  PCR for COVID-19 was positive on January 6.  She has an intermittent cough and chest congestion no pain.  Patient was evaluated by primary physician on December 17th and she was put on cefdinir and prednisone, she saw her doctor back on December 31st and she was instructed to use rescue inhaler and add Symbicort.  She was instructed to come to the Emergency department today because progressive shortness of breath and she was gaunt and faint.  Patient underwent out patient tomography scan today which showed bilateral ground glass opacities concerning for atypical pneumonia,  no signs of PE or dissection.  Patient presented with fever, tachycardia, tachypnea and hypoxia requiring initially BiPAP.  At this time on 6 L via nasal cannula maintaining oxygen saturations around 96%.  Chest x-ray findings of bilateral patchy ground-glass opacities compatible with pneumonia.  No focal airspace consolidation. Laboratory obtained and notable for lymphopenia.  ProBNP 6300.  Electrolytes sodium 126  pg/mL.   Otherwise unremarkable. Pertinent treatment in emergency department include supplemental oxygen, IV fluids and antibiotics to cover for pneumonia.
patient got a full dose for her third shot which was 0.5 ml instead of 0.25 ml, i called her the day after her vaccine and she was fine, was not experiencing any side effects
Nausea; This case was reported by a consumer via call center representative and described the occurrence of nausea in a 81-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 1 day after receiving Shingrix, the patient experienced nausea. On an unknown date, the outcome of the nausea was recovered/resolved.   It was unknown if the reporter considered the nausea to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The reporter's father experienced nausea the next day after receiving the first dose of the Shingrix vaccine.  The nausea resolved within one day. The reporter unable to obtain additional details. The reporter was unable to provide additional details. This was 1 of 4 linked cases reported by the same reporter.
Back pain, stiffness from neck to lower back, aches so bad had hard time putting weight on legs to walk
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 15-MAY-2015, the patient was vaccinated with an improperly stored dose of RECOMBIVAX HB 10 microgram/1 ml (lot#J010613, expiration date 11-JUN-2016). No adverse effects were reported. This specified lot number vaccine was exposed to temperature excursion four times. The total cumulative excursion time (hour), the lowest recorded temperature (Fahrenheit degree/ Celsius) and the type of excursion (R/F) for each time were 72, unknown and R: 48, 1 and R: 48, 0 and R: 24, -1 and R. The storage criteria was refrigerator (R). This is one of several reports received from the same source. Additional information has been requested.
5 year old cardiac pt (Double inlet (L) ventricle) not ill. Received VZV and KINRIX and within two minutes became itchy and within 5 minutes developed hives, swollen lips and tongue and became slightly cyanotic. EPIPEN Jr administered in office and 911 called and child taken to ER. BENADRYL given. No secondary reaction. No further meds needed. Observed for observation due to severity of reaction and his cardiac history.
Death  5/1/2021 Causes of death listed on death certificate: 1) Cardiac arrest  2) Failure to thrive  3) Parkinson's Disease  4) COVID-19 infection   4/2021  Other: Coronary artery disease
Chills for about an hour or so. Body aches most of the next day with a 102-degree fever after taking Tylenol. Temp of 100 degrees in the late afternoon of the 3rd day. Red arm with some itchiness.
PATIENT WAS TAKEN TO THE ER WITH 12-14 GREEN WATERY STOOLS. ADMIT WITH DEHYDRATION AND GIVEN IV FLUIDS
Two days after receiving a Pneumococcal vaccine the injection site was red, raised, and warm to touch. Determined to be an injection site reaction. Pt tx with hydrocortisone 1% cream topically with resolution.
improperly stored administered ROTATEQ; This spontaneous report was received from a consumer and refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided.  On 20-JUN-2023, the rotavirus vaccine, live, oral, pentavalent (ROTATEQ) underwent temperature excursion for 6 hours 34 minutes 0 seconds in temperature 34.9 F (-17.7 Celsius degrees). On 03-JUL-2023, the rotavirus vaccine, live, oral, pentavalent (ROTATEQ) underwent temperature excursion for 7 hours 33 minutes 0 seconds in temperature 51.4 F (10.7 Celsius degrees). On 04-JUL-2023, the rotavirus vaccine, live, oral, pentavalent (ROTATEQ) underwent temperature excursion for 24 hours 0 minutes 0 seconds in 51.1 F (10.6 Celsius degrees). On 05-JUL-2023, the rotavirus vaccine, live, oral, pentavalent (ROTATEQ) underwent temperature excursion for 9 hours 27 minutes 0 seconds in 50.7 F (10.4 Celsius degrees).  On 06-JUL-2023, this rotavirus vaccine, live, oral, pentavalent (ROTATEQ) was administered to a patient, oral liquid, at dose of 2 milliliter, route of administration defaulted to oral, lot #1968385 was valid, expiration date 22-MAY-2023 for prophylaxis (product storage error).  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2307USA009292:mother case US-009507513-2307USA009885:
Fever that was 3.5 higher than my normal temperature, severe headache that lasted for 5 days, extreme weakness, fatigue, nausea, no appetite. Could not do any of my normal chores, or exercise. My doctor had me take an 800mg of Motrin and that did nothing with the severe headache. Very bad chills. I had the two other Pfizer vaccines and just had a normal reaction. This was the booster. My arm hurt where the injection was, but that did not concern me. I was like this for a full week. I am still weak and very easily fatigued.
Day after flu shot, fever of 101.5, aches, weakness. 2nd day fever of 100, weakness.
Left leg below the knee swallon twice the size as right li eg happened on 1st shot started to go down. Second shot on 3/10/21 swollen once again even worse also area is red
Angioedema-orbital swelling both and lip swelling ~1 day after receiving Hep A vaccine-seen by emergency doctor and given Benadryl with marked improvement.